Vorapaxar for Secondary Prevention after Myocardial Infarction According to Aspirin Dose - Insights from the TRA2 degrees P-TIMI50 Trial

Benjamin M. Scirica,Marc P. Bonaca,Eugene Braunwald,Amadeo Betriu,David J. Moliterno,Ramon Corbalan,Sabina A. Murphy,David A. Morrow

Circulation（2012）

引用 24|浏览12

暂无评分

摘要

Background: In patients with a recent MI, aspirin (ASA) dose varies considerably depending on local practice patterns. Vorapaxar inhibits thrombin-mediated platelet activation by blocking the prote...

查看译文

关键词

Thrombosis,Platelet receptor blockers,Antiplatelet drugs

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要